ⓘ Spartalizumab

                                     

ⓘ Spartalizumab

Spartalizumab is a monoclonal antibody that is being investigated for melanoma.

This drug is being developed by Novartis. In 2018, spartalizumab undergoing phase III clinical trials.

                                     
  • approved to treat melanoma and lung cancer and is produced by Merck. Spartalizumab PDR001 is a PD - 1 inhibitor currently being developed by Novartis to
  • As of 2017, at least five PD - 1 inhibitors were under development. Spartalizumab PDR001 is a PD - 1 inhibitor, developed by Novartis to treat both solid
  • choroidal and retinal neovascularization Sontuzumab mab humanized episialin Spartalizumab mab humanized PDCD1, CD279 melanoma Stamulumab mab human myostatin muscular